Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare autoimmune condition that primarily affects small- and medium-sized blood vessels. It most commonly involves the respiratory tract, including the sinuses, nasal cavity, and lungs. However, GPA can also affect other parts of the body, such as the kidneys, skin, nerves, and joints.

GPA belongs to a group of inflammatory conditions known as vasculitis. The term vasculitis refers to inflammation of the blood vessels, which can cause damage to the affected vessels and surrounding tissues.

Granulomatosis with Polyangiitis (GPA) is a serious condition that requires prompt and effective treatment. Early and appropriate treatment is important to control inflammation, prevent further damage to blood vessels and affected organs, and reduce the risk of complications.

Granulomatosis with Polyangiitis (GPA) is a rare condition, estimated to affect approximately 1 in every 25,000 people. It most commonly develops in middle-aged adults, although it can occur at any age, affecting both younger and older individuals.

Granulomatosis with Polyangiitis (GPA) often develops gradually, with symptoms appearing slowly over time. Early symptoms, such as fever, fatigue, muscle aches, and unexplained weight loss, can sometimes be mistaken for an infection or even cancer.

Most people with GPA initially seek medical attention because of symptoms affecting their respiratory tract. Signs and symptoms of respiratory involvement may include:

• Chronic (long-term) sinus problems
• Frequent nosebleeds
• Sores or ulcers in the nose and/or mouth
• Recurrent ear infections or hearing loss
• Shortness of breath
• Persistent or chronic cough
• Coughing up blood
• Recurrent lung problems, including inflammation that may resemble pneumonia
• Inflammation and narrowing of the trachea (windpipe). Although uncommon, this can become serious if it restricts airflow.

Less commonly, GPA affects the kidneys. When this occurs, symptoms may include swelling of the legs, arms, or face due to fluid retention, as well as frothy or foamy urine caused by protein leaking into the urine.

Other symptoms may include joint and muscle pain, skin rashes, and inflammation of the eyes, such as uveitis or iritis.

In rare cases, GPA can affect the nerves, causing weakness or loss of muscle function. One example is foot drop, a condition in which a person has difficulty lifting the front part of their foot.

Very rarely, GPA can cause inflammation of the tissue surrounding the heart, a condition known as pericarditis.

Granulomatosis with Polyangiitis (GPA) can develop gradually, making it difficult to recognize and diagnose in its early stages. In some cases, it may take several years before an accurate diagnosis is made, while in others, the signs and symptoms are more obvious from the beginning.

GPA is usually diagnosed by a specialist physician, depending on which parts of the body are affected. A rheumatologist, who specializes in arthritis and autoimmune diseases, is often involved in diagnosing and managing the condition. If the respiratory tract or lungs are affected, a respirologist (respiratory and lung specialist) may be involved. If the kidneys are affected, a nephrologist (kidney specialist) may also be consulted.

The diagnostic process typically begins with a detailed medical history and a thorough physical examination. This is generally followed by various investigations, which may include blood tests, X-rays, and other imaging or diagnostic tests to help confirm the diagnosis and determine which organs are affected.

Blood Tests

Looking for inflammation: Granulomatosis with Polyangiitis causes inflammation in the body so these tests are expected to have abnormal results. Common tests include a Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP).

Looking for an immune response against white blood cells: The Anti-Neutrophil Cytoplasmic Antibody (ANCA) test looks for antibodies that attack proteins associated with neutrophils (white blood cells). The most common ANCA type is the c-ANCA also known as the anti-PR3 antibody.

Looking for anemia (low hemoglobin in the blood): Low hemoglobin (anemia) can result from inflammation. The ferritin levels can be tested which measure iron stores and can tell if the anemia is a result of low iron stores.

Looking at kidney function: Creatinine is a common blood test that looks at how well the kidneys are working. Abnormally high levels of creatinine can indicate a problem and can mean that the kidneys are involved.

Urine Tests

Urinalysis tests for kidney involvement: Urine tests look for protein and/or blood in the urine is a sign that the kidneys may be involved.

Scans

Chest x-rays and/or CT scans: looking for signs of airway and lung involvement

CT scans or MRIs of the head and neck: looking for involvement of the upper respiratory tract

Breathing Test

Pulmonary Function Tests (PFTs) looking for lung involvement: Pulomnary Function Testing is often used to document the presence of lung involvement and follow the lungs to determine if the disease is improving.

Nerve Test

Tests for nerve involvement: Electromyography and Nerve Conduction Studies can be performed to look for nerve involvement

Heart Test (ECG/EKG)

Test for heart involvement: An echocardiogram is an ultrasound of the heart that looks for heart involvement

The exact cause of Granulomatosis with Polyangiitis (GPA) is not known. However, it is believed to be an autoimmune disease in which the body’s immune system mistakenly attacks its own blood vessels, resulting in inflammation and potential tissue damage.

Researchers also believe that environmental factors may play a role in triggering the development of GPA, particularly in people who are genetically susceptible to the condition. However, the specific environmental triggers responsible for the development of the disease have not yet been identified.

Granulomatosis with Polyangiitis (GPA) should be treated promptly and effectively to control inflammation and prevent serious damage to the blood vessels, respiratory tract (including the lungs), kidneys, and other vital tissues and organs.

Medications used to treat GPA generally fall into two main categories:

• Induction therapy: These medications are used initially to bring the disease under control as quickly as possible by reducing inflammation and controlling disease activity.
• Maintenance therapy: Once the disease is under control, these medications are used over the longer term to maintain remission, prevent relapses, and reduce the risk of further organ damage.

Corticosteroids, such as prednisone, along with medications like cyclophosphamide and rituximab, are commonly used to bring Granulomatosis with Polyangiitis (GPA) under control. These medications work by suppressing the immune system, reducing inflammation, and controlling disease activity.

Once the disease has entered remission (when symptoms have improved or resolved and inflammation is controlled), induction medications may be gradually reduced (tapered) or discontinued, depending on the medication used and the individual’s response to treatment. Maintenance therapy is then used to help keep the disease in remission and prevent relapses.

Azathioprine, mycophenolate mofetil (or mycophenolic acid), and methotrexate are medications commonly used for long-term maintenance therapy in people with Granulomatosis with Polyangiitis (GPA). These medications generally take longer to become effective but help keep the disease under control and maintain remission. Rituximab is also used as a long-term maintenance treatment and has shown good results in preventing disease relapses.

Maintenance medications may be started while induction therapy is still ongoing, allowing the treatments to overlap. Unlike induction medications, which are used to bring the disease under control, maintenance medications are generally continued over the longer term to help sustain remission and reduce the risk of relapse.

Medications such as prednisone are commonly used to reduce inflammation and help control Granulomatosis with Polyangiitis (GPA). By controlling inflammation, prednisone can also help prevent or limit long-term damage to affected tissues and organs.

Prednisone is an effective medication for managing inflammation associated with GPA. In some cases, high doses may initially be given intravenously (through a vein) in the hospital. After a few days, treatment is usually switched to oral prednisone (tablets). As symptoms improve and markers of inflammation return to normal, the prednisone dose is gradually reduced, a process known as tapering.

Although prednisone can be very effective, long-term use may cause significant side effects. It is important to discuss the potential risks and benefits of treatment with your physician or rheumatologist.

For individuals who experience joint inflammation, corticosteroid (cortisone) injections directly into the affected joint may also provide relief. This treatment option should be discussed with your rheumatologist.

Cyclophosphamide is an immunosuppressive medication that is often used in combination with prednisone to bring Granulomatosis with Polyangiitis (GPA) under control. It works by suppressing the immune system and reducing the inflammation that causes damage to blood vessels and affected organs.

Cyclophosphamide can be given orally (by mouth) or intravenously (through an infusion into a vein). When there is severe involvement of the lungs, kidneys, or nervous system, intravenous treatment may be preferred.

Because cyclophosphamide suppresses the immune system, it can increase the risk of infections. It is important to watch for signs of infection, particularly fever, and seek prompt medical advice if these occur.

Cyclophosphamide can also affect fertility and may reduce the ability to have children. Anyone considering this treatment should discuss potential fertility risks and options for fertility preservation with their physician before starting therapy.

Ankylosing spondylitis (AS) should be diagnosed early and managed effectively to control inflammation, maintain spinal flexibility, and preserve joint mobility. Early treatment can help slow disease progression and reduce the risk of long-term complications, including the fusion of bones in the spine.

Although existing structural damage caused by AS cannot usually be reversed with medication, appropriate treatment can help relieve pain, reduce inflammation, improve mobility, and preserve physical function. Regular follow-up appointments with a rheumatologist are essential, along with completing any recommended blood tests and imaging scans to monitor disease activity and assess treatment effectiveness.

The management of ankylosing spondylitis generally involves two key approaches:

• Physical therapy and exercise: Regular physical activity, physiotherapy, and daily stretching can help reduce stiffness, maintain flexibility, improve posture, and support overall mobility.
• Medication: Medications can help control inflammation, relieve pain, and improve physical function and quality of life.

A summary of the main treatment options available to help manage ankylosing spondylitis and improve patients’ quality of life is provided below.

Physical therapy and regular exercise are essential components of managing ankylosing spondylitis (AS). They help reduce stiffness and pain, maintain spinal flexibility, improve posture, and preserve joint mobility.

A physiotherapist can develop an individualized exercise program that includes stretching, strengthening, posture training, and mobility exercises tailored to the patient’s needs and abilities. Daily stretching and low-impact activities, such as swimming and walking, can help maintain flexibility and improve overall physical function.

Consistency is important, as regular exercise can help manage symptoms and maintain mobility over time. Although physical therapy cannot reverse existing bone fusion, it can help preserve function, reduce discomfort, and support a better quality of life.

Ankylosing spondylitis (AS) is associated with an increased risk of cardiovascular disease. Therefore, it is important for people with AS to monitor and maintain healthy blood pressure and cholesterol levels to support heart health.

For individuals with diabetes, keeping blood glucose levels within the recommended range is essential to reduce the risk of complications and maintain overall health.

Smoking cessation is also strongly encouraged for people with AS. Smoking is associated with poorer disease outcomes, increased spinal damage, and reduced lung function. Quitting smoking can help improve overall health and may reduce the risk of complications associated with the condition.

In severe cases of ankylosing spondylitis (AS), advanced joint damage and spinal fusion can lead to significant pain, stiffness, reduced mobility, and physical deformity. When these complications severely affect a person’s quality of life, surgery may be considered.

One of the most common surgical procedures is total hip replacement, in which a damaged hip joint is replaced with an artificial joint. This procedure can help relieve pain, improve mobility, and restore physical function in people with severe hip involvement.

Spinal surgery is more complex and is generally reserved for carefully selected patients with severe spinal deformities or other serious complications. Depending on the individual’s condition, surgery may help correct deformity, improve posture, and enhance function. The decision to proceed with surgery depends on the extent of the damage, the severity of symptoms, and the potential benefits and risks of the procedure.

Medications used to treat ankylosing spondylitis (AS) can be divided into two main categories:

• Medications that relieve symptoms: These include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics (pain relievers), and corticosteroids, such as prednisone. They may help reduce pain and inflammation, although their effectiveness varies depending on the medication and how it is administered.
• Medications that control disease activity: These include biologic therapies and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), which help control inflammation and reduce disease activity. Conventional DMARDs may be useful for certain symptoms affecting peripheral joints, but they generally have limited effectiveness for inflammation confined to the spine.

Before starting any new medication, patients should consult their healthcare provider or pharmacist about potential interactions with alcohol, prescription medications, over-the-counter products, supplements, and complementary therapies.

Although some complementary approaches, such as exercise and physiotherapy, can support symptom management, there is limited scientific evidence that natural remedies or alternative therapies alone can effectively control AS-related inflammation or prevent long-term joint damage. These approaches should not replace prescribed medical treatment.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat ankylosing spondylitis (AS). They help reduce inflammation, relieve joint pain, and improve stiffness and mobility.

Several NSAIDs are available, including ibuprofen, naproxen, and celecoxib. If one medication does not provide sufficient relief or causes troublesome side effects, a doctor may recommend trying a different NSAID, depending on the patient’s medical history and individual needs.

Although NSAIDs can effectively manage symptoms, current evidence does not establish that they consistently prevent the long-term structural progression of AS. Their primary role is to control pain and inflammation and improve daily functioning.

Because NSAIDs can cause side effects, including stomach irritation, ulcers, kidney problems, and an increased risk of cardiovascular complications, patients should work with their healthcare provider to determine the most appropriate medication and dose.

Analgesics are medications used to relieve pain associated with ankylosing spondylitis (AS). However, they do not directly reduce the underlying inflammation or prevent further joint damage caused by the disease.

Analgesics range from commonly used pain relievers, such as acetaminophen (Tylenol), to stronger opioid medications, such as morphine, which may be prescribed in specific circumstances.

The choice of analgesic depends on the severity of the pain, the patient’s overall health, and their response to other treatments. Stronger pain medications, particularly opioids, require careful medical supervision because of the risk of side effects, dependence, and other complications.

Corticosteroids, such as prednisone, are medications that reduce inflammation and may help relieve symptoms in certain people with ankylosing spondylitis (AS).

However, oral corticosteroids are generally not recommended for the routine treatment of inflammation affecting the spine, as they have limited evidence of benefit for this type of disease. In selected cases, short courses of corticosteroids may be considered to manage specific inflammatory symptoms or complications.

Long-term use of prednisone can cause significant side effects, including weight gain, osteoporosis, high blood pressure, elevated blood sugar, and an increased risk of infection. Therefore, treatment decisions should be made in consultation with a rheumatologist, who can help patients weigh the potential benefits against the risks and identify the most appropriate treatment approach.

Biologic medications are used to treat ankylosing spondylitis (AS) when symptoms and inflammation are not adequately controlled with nonsteroidal anti-inflammatory drugs (NSAIDs), or when these medications are unsuitable. Biologics target specific components of the immune system involved in the inflammatory process and can help reduce pain, stiffness, and disease activity while improving mobility and quality of life.

The first biologic medications used to treat AS were tumour necrosis factor (TNF) inhibitors, introduced in the late 1990s. These medications represented a major advance in treatment for people whose symptoms did not respond sufficiently to conventional therapies.

Disease-modifying antirheumatic drugs (DMARDs) are commonly used to treat rheumatoid arthritis (RA) and other inflammatory conditions. However, their role in treating ankylosing spondylitis (AS) is more limited because many conventional DMARDs are not effective against inflammation primarily affecting the spine.

Medications such as methotrexate and sulfasalazine generally do not provide significant relief for spinal pain or stiffness associated with AS.

However, conventional DMARDs may be beneficial when AS affects peripheral joints, such as the knees, ankles, or wrists, particularly when these joints are persistently swollen and inflamed. Sulfasalazine may be considered in these cases, while methotrexate has more limited evidence of benefit for AS-related peripheral arthritis.

A rheumatologist can determine whether a DMARD is appropriate based on the joints involved, the severity of symptoms, and the patient’s response to other treatments.

Ankylosing spondylitis (AS) is a chronic inflammatory disease involving an abnormal immune response that causes the body to attack its own healthy tissues. The exact cause of this immune response is not fully understood, although genetic and environmental factors are believed to play a role.

AS is considered a systemic rheumatic disease because it can affect not only the spine and joints but also other parts of the body, including the eyes, lungs, and intestines.

Early diagnosis and treatment of ankylosing spondylitis (AS) are essential to help manage the condition and slow its progression.

Appropriate treatment can reduce inflammation, relieve pain and stiffness, maintain mobility, and help prevent long-term complications, including damage to the spine. Effective management may also help reduce the risk of complications associated with chronic inflammation, such as cardiovascular disease, and support overall health and well-being.

There is no specific diet proven to stop AS or reverse spinal changes. A Mediterranean-style pattern—vegetables and fruit, whole grains, legumes, nuts, fish, and unsaturated fats—is a reasonable approach for overall health. Foods such as tomatoes and bell peppers can be included, but they shouldn’t be considered treatments for AS.

Tomatoes and arthritis

Tomatoes can be a nutritious addition to an arthritis-friendly diet, although they do not cure arthritis or directly reverse joint damage.

• Lycopene: Tomatoes are particularly rich in lycopene, an antioxidant that helps protect cells from oxidative stress. Cooked tomatoes and tomato products can provide especially well-absorbed lycopene.

• Vitamin C: Supports collagen formation and normal connective-tissue function.

• Antioxidants: Tomatoes contain vitamin C, carotenoids, and other plant compounds that contribute to overall antioxidant intake.

• Potential anti-inflammatory effects: Laboratory and observational research suggests that compounds in tomatoes may influence inflammatory pathways, but evidence that eating tomatoes significantly reduces arthritis pain or inflammation in people is still limited.

• Heart health: Tomatoes can contribute to a heart-healthy diet, which is particularly relevant for people with rheumatoid arthritis, because RA is associated with increased cardiovascular risk.

Some people with arthritis report that tomatoes or other nightshade vegetables worsen their symptoms. There isn’t strong scientific evidence that tomatoes generally cause arthritis inflammation or should routinely be avoided. If you consistently notice symptoms after eating a particular food, discussing this pattern with a healthcare professional or dietitian can be more useful than eliminating foods unnecessarily.

For osteoarthritis, tomatoes are best viewed as part of an overall nutritious eating pattern. For rheumatoid arthritis, diet can complement medical treatment but shouldn’t replace disease-modifying medication when it is prescribed.

Rituximab

Rituximab is a type of biologic medication that targets specific cells in the immune system involved in the inflammation associated with Granulomatosis with Polyangiitis (GPA). It has been shown to be an effective treatment for GPA and is an established alternative to cyclophosphamide for inducing remission.

Although rituximab can be more expensive than some conventional treatments, it may be an option for people concerned about the potential effects of cyclophosphamide on fertility. Unlike cyclophosphamide, rituximab is not generally associated with the same risk of fertility damage. However, its use during pregnancy requires careful medical consideration.

Rituximab is also increasingly used as a long-term maintenance therapy to help keep the disease in remission and reduce the risk of relapse.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) are medications commonly used to treat rheumatoid arthritis and other inflammatory conditions. Several DMARDs are also used in the treatment of GPA, including:

• Azathioprine (Imuran)
• Methotrexate
• Mycophenolate mofetil or mycophenolic acid

These medications are commonly used as maintenance therapy once the disease is under control and remission has been achieved. In selected cases of milder GPA, certain DMARDs may also be used as part of the initial treatment approach.

Many conventional DMARDs take approximately 6–12 weeks to begin working. As a result, some people may not notice an immediate improvement after starting treatment. It is important to continue taking these medications as prescribed, even when there is no noticeable effect at first, as they work gradually to control inflammation and help maintain remission.

Your physician or rheumatologist will determine which medication is most appropriate based on the severity of the disease, the organs involved, and your individual response to treatment.

Living with Ankylosing spondylitis can affect mental health in several ways. Research consistently shows that people with AS have higher rates of anxiety and depression than the general population, although not everyone with AS experiences these challenges.

Some of the reasons include:

• Chronic pain: Ongoing pain can increase stress, irritability, and emotional exhaustion.
• Fatigue: Persistent fatigue can make it harder to work, socialize, or enjoy activities, contributing to low mood.
• Sleep disruption: Pain and stiffness often interfere with sleep, which can worsen anxiety and depression.
• Reduced mobility: Difficulty with movement or physical limitations may lead to frustration or loss of independence.
• Uncertainty about the future: Concerns about disease progression, work, or relationships can increase emotional distress.
• Inflammation: Some evidence suggests that inflammation itself may contribute to changes in mood, although this relationship is still being studied.